From left -  Lee Jiau Jiunn, Chief Executive Officer, AmMetLife and Hareeff Muhammed, Chief Executive Officer, Pantai Premier Pathology with the signed MOU. 
 

KUALA LUMPUR, Nov 9 (Bernama) -- AmMetLife Insurance Berhad (“AmMetLife”) and Pantai Premier Pathology Sdn. Bhd. (“Pantai Premier Pathology”) have signed a Memorandum of Understanding (MOU) extending their existing collaboration for two more years. Through this collaboration, AmMetLife’s medical plan customers will be able to access preferential rates when undergoing genomic testing for cancer at Pantai Premier Pathology’s network of 14 medical facilities across Malaysia.

The MOU covers 47 different tests, including BRCA for breast and ovarian cancer as well as EGFR for lung cancer, which can help to assist physicians in making more informed treatment decisions for cancer patients.

The MOU was signed by Lee Jiau Jiunn, Chief Executive Officer, AmMetLife and Hareeff Muhammed, Chief Executive Officer, Pantai Premier Pathology during a virtual ceremony attended by senior management and employees of both companies.  

According to Lee, “The pandemic has driven greater awareness of people’s health and wellbeing. Individuals who may have never considered life or medical insurance before are now beginning to understand how it can support their family’s health and financial security. At AmMetLife, we are committed to supporting our customers navigate this health crisis by offering solutions that can help them make informed choices and seek the most effective treatment available. Through our ongoing collaboration with Pantai Premier Pathology, genomic testing is now easily accessible and affordable to many Malaysians suffering from cancer.”

Under this MOU, oncologists, cancer specialists and other medical professionals under Pantai Premier Pathology are able to provide AmMetLife customers with the relevant genomic tests and interpretation of results at preferential rates.

According to Hareeff Muhammed, “The ability to read through the human genome to identify specific mutations causing cancer will enable doctors to understand the presence or severity of a patient’s condition and manage their care and treatment appropriately.” 

“Pantai Premier Pathology is able to enhance patient care and clinical outcomes as we have state-of-the-art technology and a comprehensive molecular laboratory, which has been accredited by the College of American Pathologists,” Hareeff added.

This MoU will also further pave the way for both AmMetLife and Pantai Premier Pathology to work together in raising cancer awareness and its associated risk factors through educational programmes and public health talks.

About AmMetLife
AmMetLife is a strategic partnership between AMMB Holdings Berhad (AmBank Group) and MetLife International Holdings LLC (MetLife). AmMetLife offers a comprehensive range of life assurance and wealth protection solutions distributed through a combination of over 200 AmBank and AmMetLife branded branch offices, in addition to the strength of its authorised life insurance agents nationwide. The strategic partnership combines the international expertise and financial strength of MetLife with the local strength and reach of AmBank Group to create a customer-centric and modern life assurance solutions provider in Malaysia.

About Pantai Premier Pathology
Pantai Premier Pathology Sdn. Bhd. provides a comprehensive range of quality diagnostics and analytical laboratory testing services to referring medical practitioners including both general practitioners and specialist doctors; from medical clinics and medical centres, to large tertiary hospitals in Malaysia.
Pantai Premier Pathology is part of Parkway Pantai, one of Asia’s largest integrated private healthcare providers operating in Malaysia, Singapore, India, China, Brunei and United Arab Emirates. For over 40 years, its Mount Elizabeth, Gleneagles, Pantai, Parkway and Fortis brands have established themselves as the region’s best known brands in private healthcare, synonymous with best-in-class patient experience and outcomes. In Malaysia, Parkway Pantai is the second largest private healthcare provider operating 15 hospitals including eleven Pantai Hospitals and four Gleneagles Hospitals as well as ancillary healthcare services including Pantai Integrated Rehab and Pantai Premier Pathology. It is part of IHH Healthcare, one of the world’s largest healthcare groups by market capitalisation. IHH operates more than 15,000 licensed beds across 80 hospitals in 11 countries worldwide, offering the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services including medical education. 

Source: AmBank Group

FOR MORE INFORMATION, PLEASE CONTACT: 
Corporate Communications Department 
Email: AmMetLife-Communicator@ammmetlife.com

--BERNAMA